Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00859937 · BASELINE

Baseline characteristics

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors · Source last updated 2018-04-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      40
    2. group Id
      BG001
      value
      14
    3. group Id
      BG002
      value
      54
    units
    Participants
groups
  1. description
    Patients with Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    BG000
    title
    Adenoid Cystic Carcinoma
  2. description
    Patients with non Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    BG001
    title
    Non Adenoid Cystic Carcinoma
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          30
          upper Limit
          82
          value
          56
        2. group Id
          BG001
          lower Limit
          20
          upper Limit
          71
          value
          56
        3. group Id
          BG002
          lower Limit
          20
          upper Limit
          82
          value
          56
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          22
        2. group Id
          BG001
          value
          4
        3. group Id
          BG002
          value
          26
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          18
        2. group Id
          BG001
          value
          10
        3. group Id
          BG002
          value
          28
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      40
    2. group Id
      BG001
      value
      14
    3. group Id
      BG002
      value
      54
    units
    Participants
groups
  1. description
    Patients with Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    BG000
    title
    Adenoid Cystic Carcinoma
  2. description
    Patients with non Adenoid cystic carcinoma of malignant salivary gland tumors receive oral dasatinib (70mg) twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    BG001
    title
    Non Adenoid Cystic Carcinoma
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          30
          upper Limit
          82
          value
          56
        2. group Id
          BG001
          lower Limit
          20
          upper Limit
          71
          value
          56
        3. group Id
          BG002
          lower Limit
          20
          upper Limit
          82
          value
          56
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          22
        2. group Id
          BG001
          value
          4
        3. group Id
          BG002
          value
          26
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          18
        2. group Id
          BG001
          value
          10
        3. group Id
          BG002
          value
          28
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice